Ogilvy-Stuart. A L AL; Stirling. H F HF; Kelnar. C J CJ; Savage. M O MO; Dunger. D B DB; Buckler. J...
In a small study of kids who lost growth hormone after brain radiation, giving them a synthetic growth‑hormone‑releasing hormone (sermorelin) twice a day for a year roughly doubled their growth speed and was safe, but the boost was still smaller than what you get from actual growth‑hormone injections.
Chen. R G RG; Shen. Y N YN; Yei. J J; Wang. C F CF; Xie. D H DH; Wang. X H XH; Zhou. J D JD; Chen. C...
In kids with growth‑hormone deficiency, daily injections of the GHRH peptide (sermorelin) grew them about 9 cm a year, while direct growth‑hormone shots grew them about 15 cm a year, so the peptide was noticeably less effective. Antibodies formed against the peptide but didn’t affect growth, and side‑effects were mild.
Cervini. L A LA; Donaldson. C J CJ; Koerber. S C SC; Vale. W W WW; Rivier. J E JE
The study mapped which parts of the human growth‑hormone‑releasing hormone (GHRH) peptide are most important for activating its receptor. By swapping individual amino acids with alanine or adding structural constraints, the researchers found several modified versions that work 2‑17 times better than the natural fragment in lab tests. However, the work was done only in vitro, with no data on how these changes affect humans, safety, or dosing.
Thorner. M M; Rochiccioli. P P; Colle. M M; Lanes. R R; Grunt. J J; Galazka. A A; Landy. H H; Eengra...
A year‑long study gave kids who lack growth hormone a daily shot of sermorelin (30 µg per kg). Their growth speed roughly doubled in the first six months and stayed high after a year, with no major side effects or changes in blood sugar or IGF‑1 levels.
Lin. J J; Barb. C R CR; Kraeling. R R RR; Rampacek. G B GB
In pig pituitary cells, the growth hormone releasing factor (GRF, the same peptide used in sermorelin) boosted growth hormone release and lowered the amount of the long form leptin receptor. This suggests GRF can directly affect how the pituitary responds to leptin, a hormone that regulates appetite and metabolism.
Grossman. A A; Savage. M O MO; Blacklay. A A; Ross. R M RM; Plowman. P N PN; Preece. M A MA; Coy. D...
The study shows that giving a synthetic version of growth‑hormone‑releasing hormone (GHRH) can quickly raise growth hormone levels in kids who have a deficiency, and that regular dosing keeps the hormone elevated over days. However, the research was done in children with medical growth problems, not in healthy adults looking for performance or anti‑aging benefits.
The study shows that synthetic growth‑hormone‑releasing peptides (like sermorelin) trigger a dose‑dependent release of growth hormone from pituitary cells, and that this effect can be altered by other brain chemicals such as vasopressin and substance P, meaning hormone release is a complex, interacting system.
In normal mice, giving the growth‑hormone‑releasing peptide (sermorelin) quickly spikes GH levels, but in dwarf ‘Little’ mice that have a pituitary defect, the same peptide does nothing and doesn’t boost growth. This shows the peptide only works when the pituitary can store and release GH.
Heiman. M L ML; Porter. J R JR; Nekola. M V MV; Murphy. W A WA; Hartman. A D AD; Lance. V A VA; Coy....
In obese Zucker rats, the pituitary’s response to a growth‑hormone‑releasing peptide (like sermorelin) is much weaker, needing far higher amounts to trigger GH release, while the same pituitary is more sensitive to a luteinizing‑hormone‑releasing peptide, producing more LH and FSH at lower doses. This shows obesity can blunt GH‑secretagogue effects but boost gonadotropin‑secretagogue effects, at least in this animal model.
McCutcheon. S N SN; Bauman. D E DE; Murphy. W A WA; Lance. V A VA; Coy. D H DH
In dairy cows, injecting sermorelin (a growth‑hormone‑releasing peptide) caused a quick jump in blood growth hormone – the short 24‑amino‑acid version peaked at about 14 ng/ml in 10 minutes and fell back to normal within an hour, while the longer 29‑amino‑acid version peaked around 30 ng/ml and stayed high for several hours. Even very high doses didn’t boost milk production, suggesting the hormone spike is short‑lived and not functionally powerful.
The study tested sermorelin, a growth‑hormone‑releasing peptide, in kids with growth‑hormone deficiency and found it boosted their own GH levels in about half of the cases, especially in those with isolated deficiency. This hints that stimulating the body’s own GH could someday replace daily GH shots, but the work is in children and not yet ready for adult self‑experimenters.
Pasqualini. T T; Ferraris. J J; Fainstein-Day. P P; Eymann. A A AA; Moyano Caturelly. S S; Ruiz. S S...
A small study gave a growth‑hormone‑releasing peptide (sermorelin) to nine kids with kidney disease. Five of them grew faster, but the others didn’t, and the treatment didn’t change kidney function. The results are modest and only apply to children with chronic renal failure, not healthy adults.
Pérez-Romero. A A; Rol de Lama. M A MA; Ariznavarreta. C C; Tresguerres. J A JA
In young female rats, giving a lot of the growth‑hormone‑releasing peptide (GHRH) for a few weeks raised their body weight a bit and slightly increased pituitary growth hormone, but a steady low‑dose release only boosted blood GH without making them heavier. Adding a somatostatin drug cancelled the GHRH benefits on the pituitary. The results show that chronic GHRH can raise GH levels, but it doesn’t reliably boost growth, and mixing it with somatostatin can block its effects.
Zarandi. M M; Serfozo. P P; Zsigo. J J; Deutch. A H AH; Janaky. T T; Olsen. D B DB; Bajusz. S S; Sch...
Researchers made several modified versions of the growth‑hormone‑releasing hormone (the same family as sermorelin) and tested them in lab dishes. Some of the new peptides were up to six times more active than the standard hormone, but a few changes actually made them weaker. The work shows which tweaks help or hurt potency, but the compounds aren’t sold or tested in people yet.
Neyzi. O O; Yordam. N N; Ocal. G G; Bundak. R R; Darendeliler. F F; Açikgöz. E E; Berbero&...
In a study of children with growth hormone deficiency, daily injections of the peptide sermorelin (GHRH‑1‑29‑NH2) at a high dose helped them grow at a rate similar to those given actual growth hormone, but it didn’t improve bone age like the hormone did. Lower doses were less effective, and the peptide didn’t keep raising growth hormone levels after a test dose.
The study shows that blocking the body's own growth‑hormone‑releasing hormone (GHRH) makes a breast‑cancer cell line grow slower and die more often. This suggests that natural GHRH can act like a growth signal for some cancer cells.
The study shows that drugs that block the natural hormone GHRH can stop cancer cells from making a signaling molecule (cAMP) that helps them grow. While sermorelin is a GHRH‑like drug that boosts growth hormone, this research hints that stimulating the GHRH pathway might, in theory, support cancer cell activity, so users should be aware of a possible risk, especially if they have a history of cancer.
Brain. C C; Hindmarsh. P C PC; Pringle. P J PJ; Brook. C G CG
A study gave kids with mild growth hormone problems a tiny pump that constantly delivered a peptide called GHRH (sermorelin) under the skin. Over three to six months, their hormone levels went up and they grew faster, with no sign that the body got used to the peptide.
Dieguez. C C; Jordan. V V; Harris. P P; Foord. S S; Rodriguez-Arnao. M D MD; Gomez-Pan. A A; Hall. R...
In rats, low thyroid (hypothyroid) makes the pituitary less responsive to sermorelin, a growth‑hormone‑releasing peptide, while high thyroid (hyperthyroid) causes a smaller, later drop in response. This suggests thyroid health can influence how well sermorelin works.
Szereday. Zoltan Z; Schally. Andrew V AV; Varga. Jozsef L JL; Kanashiro. Celia A CA; Hebert. Francin...
In a mouse model of lung cancer, a drug that blocks the hormone that normally tells the body to release growth hormone (GH‑RH antagonist JV‑1‑38) slowed tumor growth by about half. The tumors had their own GH‑RH receptors and made IGF‑I, a growth‑promoting protein, and the blocker reduced IGF‑I inside the tumor without changing blood levels. This suggests that interfering with the GH‑IGF pathway can directly affect cancer cells.